1. Home
  2. PEGA vs RYTM Comparison

PEGA vs RYTM Comparison

Compare PEGA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pegasystems Inc.

PEGA

Pegasystems Inc.

BUY

Current Price

$34.79

Market Cap

6.3B

Sector

Technology

ML Signal

BUY

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

BUY

Current Price

$92.19

Market Cap

5.8B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
PEGA
RYTM
Founded
1983
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.8B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
PEGA
RYTM
Price
$34.79
$92.19
Analyst Decision
Buy
Buy
Analyst Count
10
18
Target Price
$40.00
★ $138.59
AVG Volume (30 Days)
★ 1.8M
616.9K
Earning Date
10-20-2026
11-03-2026
Dividend Yield
★ 0.35%
N/A
EPS Growth
★ 91.89
28.34
EPS
★ 0.26
N/A
Revenue
★ $682,695,000.00
N/A
Revenue This Year
$6.76
$65.10
Revenue Next Year
$8.40
$78.21
P/E Ratio
$132.81
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.10
$74.50
52 Week High
$68.10
$122.20

Technical Indicators

Market Signals
Indicator
PEGA
RYTM
Relative Strength Index (RSI) 50.79 30.67
Support Level $34.49 $82.43
Resistance Level $35.49 $99.50
Average True Range (ATR) 1.22 3.52
MACD -0.20 -0.36
Stochastic Oscillator 53.14 28.55

Price Performance

Historical Comparison
PEGA
RYTM

About PEGA Pegasystems Inc.

Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: